AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: AZD5462

First Posted Date: 2022-08-23

Last Posted Date: 2023-11-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 16

Registration Number: NCT05512806

Locations: 🇺🇸
Research Site, Brooklyn, Maryland, United States

Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: AZD6234
Drug: Placebo
Combination Product: Acetaminophen

First Posted Date: 2022-08-22

Last Posted Date: 2023-12-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 54

Registration Number: NCT05511025

Locations: 🇺🇸
Research Site, Brooklyn, Maryland, United States

Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.

Phase 1

Completed

Conditions: Healthy Female Participants

Interventions: Drug: Zibotentan
Drug: EE/LNG

First Posted Date: 2022-08-17

Last Posted Date: 2023-02-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 24

Registration Number: NCT05505162

Locations: 🇺🇸
Research Site, Brooklyn, Maryland, United States

Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy Subjects

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: CIN-107
Drug: Matching Placebo

First Posted Date: 2022-08-15

Last Posted Date: 2023-08-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 56

Registration Number: NCT05500820

Locations: 🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States

Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Combination Product: Neoadjuvant combination therapy with olaparib plus durvalumab
Drug: Neoadjuvant Olaparib monotherapy group

First Posted Date: 2022-08-11

Last Posted Date: 2025-03-04

Lead Sponsor: AstraZeneca

Target Recruit Count: 50

Registration Number: NCT05498155

Locations: 🇬🇧
Research Site, Nottingham, United Kingdom

An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Other: Placebo
Drug: Mitiperstat (AZD4831)

First Posted Date: 2022-08-09

Last Posted Date: 2024-11-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 381

Registration Number: NCT05492877

Locations: 🇬🇧
Research Site, York, United Kingdom

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Phase 2

Recruiting

Conditions: Endometrial Cancer
Gastric Cancer
Metastatic Castration-resistant Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Urothelial Cancer
Biliary Tract Cancer

Interventions: Drug: Datopotamab deruxtecan (Dato-DXd)
Drug: 5-Fluorouracil
Drug: Prednisone/ prednisolone
Drug: Capecitabine
Drug: Volrustomig
Drug: Rilvegostomig
Drug: Carboplatin
Drug: Bevacizumab
Drug: Cisplatin
Drug: Leucovorin LV

First Posted Date: 2022-08-05

Last Posted Date: 2025-05-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 582

Registration Number: NCT05489211

Locations: 🇬🇧
Research Site, Manchester, United Kingdom

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Treatment A (BGF MDI HFO with oral activated charcoal)
Drug: Treatment B (BGF MDI HFA with oral activated charcoal)

First Posted Date: 2022-07-28

Last Posted Date: 2025-05-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 108

Registration Number: NCT05477108

Locations: 🇺🇸
Research Site, Brooklyn, Maryland, United States

Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal Function

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: CIN-107

First Posted Date: 2022-07-22

Last Posted Date: 2023-08-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 33

Registration Number: NCT05470725

Locations: 🇺🇸
Genesis Clinical Trials, Tampa, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies

Phase 1

Completed

Conditions: Advanced Solid Malignancies

Interventions: Drug: Ceralasertib

First Posted Date: 2022-07-22

Last Posted Date: 2024-08-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 12

Registration Number: NCT05469919

Locations: 🇯🇵
Research Site, Chuo-ku, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy